266 related articles for article (PubMed ID: 27923049)
1. Expression of lncRNAs in Low-Grade Gliomas and Glioblastoma Multiforme: An In Silico Analysis.
Reon BJ; Anaya J; Zhang Y; Mandell J; Purow B; Abounader R; Dutta A
PLoS Med; 2016 Dec; 13(12):e1002192. PubMed ID: 27923049
[TBL] [Abstract][Full Text] [Related]
2. Molecular subtypes of glioblastoma are relevant to lower grade glioma.
Guan X; Vengoechea J; Zheng S; Sloan AE; Chen Y; Brat DJ; O'Neill BP; de Groot J; Yust-Katz S; Yung WK; Cohen ML; Aldape KD; Rosenfeld S; Verhaak RG; Barnholtz-Sloan JS
PLoS One; 2014; 9(3):e91216. PubMed ID: 24614622
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma.
Maimaiti A; Wang X; Pei Y; Nuermaimaiti N; Tuersunniyazi A; Abula Y; Feng Z; Jiang L; Shi X; Kasimu M
Aging (Albany NY); 2021 Jun; 13(11):15164-15192. PubMed ID: 34081618
[TBL] [Abstract][Full Text] [Related]
4. Prospective Series of Nine Long Noncoding RNAs Associated with Survival of Patients with Glioblastoma.
Lei B; Yu L; Jung TA; Deng Y; Xiang W; Liu Y; Qi S
J Neurol Surg A Cent Eur Neurosurg; 2018 Nov; 79(6):471-478. PubMed ID: 29959764
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNA profiles reveal three molecular subtypes in glioma.
Li R; Qian J; Wang YY; Zhang JX; You YP
CNS Neurosci Ther; 2014 Apr; 20(4):339-43. PubMed ID: 24393335
[TBL] [Abstract][Full Text] [Related]
7. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
8. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.
Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M
World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770
[TBL] [Abstract][Full Text] [Related]
9. Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma.
Dao Trong P; Rösch S; Mairbäurl H; Pusch S; Unterberg A; Herold-Mende C; Warta R
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257451
[TBL] [Abstract][Full Text] [Related]
10. Foreboding lncRNA markers of low-grade gliomas dependent on metabolism.
Lu Z; Feng Y
Medicine (Baltimore); 2022 Nov; 101(44):e31302. PubMed ID: 36343057
[TBL] [Abstract][Full Text] [Related]
11. A Prognostic Signature for Lower Grade Gliomas Based on Expression of Long Non-Coding RNAs.
Kiran M; Chatrath A; Tang X; Keenan DM; Dutta A
Mol Neurobiol; 2019 Jul; 56(7):4786-4798. PubMed ID: 30392137
[TBL] [Abstract][Full Text] [Related]
12. Identification of potential biomarkers related to glioma survival by gene expression profile analysis.
Hsu JB; Chang TH; Lee GA; Lee TY; Chen CY
BMC Med Genomics; 2019 Mar; 11(Suppl 7):34. PubMed ID: 30894197
[TBL] [Abstract][Full Text] [Related]
13. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
[TBL] [Abstract][Full Text] [Related]
14. Over-expression of lysyl oxidase is associated with poor prognosis and response to therapy of patients with lower grade gliomas.
Huang SP; Chiou J; Jan YH; Lai TC; Yu YL; Hsiao M; Lin YF
Biochem Biophys Res Commun; 2018 Jun; 501(3):619-627. PubMed ID: 29729273
[TBL] [Abstract][Full Text] [Related]
15. Identification and Validation of an Energy Metabolism-Related lncRNA-mRNA Signature for Lower-Grade Glioma.
Zhao J; Wang L; Wei B
Biomed Res Int; 2020; 2020():3708231. PubMed ID: 32802843
[TBL] [Abstract][Full Text] [Related]
16. Molecular profile of tumors with oligodendroglial morphology: Clinical relevance.
Geevar T; Pai R; Chacko G; Malepathi K; Patel B; John J; Chacko AG; Balakrishnan R; John S
Neurol India; 2018; 66(6):1726-1731. PubMed ID: 30504574
[TBL] [Abstract][Full Text] [Related]
17. An eight-mRNA signature outperforms the lncRNA-based signature in predicting prognosis of patients with glioblastoma.
Gong Z; Hong F; Wang H; Zhang X; Chen J
BMC Med Genet; 2020 Mar; 21(1):56. PubMed ID: 32188434
[TBL] [Abstract][Full Text] [Related]
18. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
19. Identification of an autophagy-related 10-lncRNA-mRNA signature for distinguishing glioblastoma multiforme from lower‑grade glioma and prognosis prediction.
Wei B; Wang L; Zhao J
Gen Physiol Biophys; 2021 Jul; 40(4):257-274. PubMed ID: 34350832
[TBL] [Abstract][Full Text] [Related]
20. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
